The case and the decision

A family has delayed bleeding after procedures, mild thrombocytopenia and absent epinephrine-induced platelet aggregation. Routine plasma clot-lysis testing is normal. An earlier genetic panel covered single-nucleotide changes and small insertions or deletions, with no validated copy-number analysis.

What both explanations do well

Both identify Quebec platelet disorder and explain why a platelet-localised fibrinolytic process can escape routine plasma testing. Primary experiments support that compartment distinction. Both also recognise that the reported panel does not resolve the known PLAU tandem-duplication question. [1] [2]

The wording worth correcting

OpenEvidence calls the isolated epinephrine response a specific laboratory clue rather than a nonspecific finding. Published laboratory descriptions treat aggregation findings as non-diagnostic. It is a useful clue in the family pattern, but not a stand-alone identification of QPD. [3]

MontMedical's provisional classification is better calibrated here. The decisive confirmation is targeted assessment of the relevant structural alteration and phenotype, rather than greater confidence in the aggregation result.

What OpenEvidence gets right—and what neither answer settles

OpenEvidence makes the practical bleeding implications prominent and correctly explains the plasma-versus-platelet problem. This is a narrow wording advantage for MontMedical, not a missed diagnosis by OpenEvidence.

Neither retained answer should be used to conclude that every possible coexisting von Willebrand disorder has been excluded. The case shows that VWF replacement does not adequately explain or control the described episode; that is a different claim.